Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in M&A / Deals

Lilly puts up to $2.75bn into Insilico alliance

 March 29, 2026

Pharmaphorum

Insilico has once again added to its roster of big pharma partners, signing a deal with Eli Lilly that includes a $115m upfront payment.

M&A / DealsRead full story

Post navigation

S16 Ep38: Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC →
← Otsuka grows in neuroplastogens with $1.225bn Transcend buy

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com